198 related articles for article (PubMed ID: 21702044)
21. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
22. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
24. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.
Ruf P; Kluge M; Jäger M; Burges A; Volovat C; Heiss MM; Hess J; Wimberger P; Brandt B; Lindhofer H
Br J Clin Pharmacol; 2010 Jun; 69(6):617-25. PubMed ID: 20565453
[TBL] [Abstract][Full Text] [Related]
26. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
27. The evolving role of catumaxomab in gastric cancer.
Lordick F; Ott K; Weitz J; Jäger D
Expert Opin Biol Ther; 2008 Sep; 8(9):1407-15. PubMed ID: 18694358
[TBL] [Abstract][Full Text] [Related]
28. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.
Woopen H; Pietzner K; Darb-Esfahani S; Oskay-Oezcelik G; Sehouli J
Med Oncol; 2012 Dec; 29(5):3416-20. PubMed ID: 22744709
[TBL] [Abstract][Full Text] [Related]
29. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M; Körfer J; Kunzmann V; Trojan J; Daum S; Schenk M; Kullmann F; Schroll S; Behringer D; Stahl M; Al-Batran SE; Hacker U; Ibach S; Lindhofer H; Lordick F
Br J Cancer; 2018 Aug; 119(3):296-302. PubMed ID: 29988111
[TBL] [Abstract][Full Text] [Related]
30. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
[TBL] [Abstract][Full Text] [Related]
31. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
32. Catumaxomab: malignant ascites: unjustified marketing authorisation.
Prescrire Int; 2010 Oct; 19(109):207-9. PubMed ID: 21180374
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Ströhlein MA; Lordick F; Rüttinger D; Grützner KU; Schemanski OC; Jäger M; Lindhofer H; Hennig M; Jauch KW; Peschel C; Heiss MM
Onkologie; 2011; 34(3):101-8. PubMed ID: 21358214
[TBL] [Abstract][Full Text] [Related]
34. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
35. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
[TBL] [Abstract][Full Text] [Related]
36. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
37. Review of catumaxomab in the treatment of malignant ascites.
Sebastian M
Cancer Manag Res; 2010 Nov; 2():283-6. PubMed ID: 21188120
[TBL] [Abstract][Full Text] [Related]
38. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
39. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Ruf P; Bauer HW; Schoberth A; Kellermann C; Lindhofer H
Cancer Immunol Immunother; 2021 Sep; 70(9):2727-2735. PubMed ID: 33837852
[TBL] [Abstract][Full Text] [Related]
40. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.
Ströhlein MA; Siegel R; Jäger M; Lindhofer H; Jauch KW; Heiss MM
J Exp Clin Cancer Res; 2009 Feb; 28(1):18. PubMed ID: 19216794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]